Amgen "outperform," target price raised

11.02.09 - Leerink Swann & Co.

NEW YORK, February 11 (newratings.com) - Analysts at Leerink Swann & Co reiterate their "outperform" rating on Amgen Inc (AMGN). The target price has been raised from $73 to $74.